Trial Profile
Transcriptome and Metabolic Analyses of CHAPLE Disease Patients With or Without Eculizumab Treatment
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Immune haemolysis; Inborn genetic disorders; Thrombotic microangiopathy
- Focus Pharmacodynamics
- Acronyms CHAPLEOMIC
- 04 Aug 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified August 2019).
- 13 Aug 2019 Planned primary completion date changed from 15 Jun 2019 to 15 Sep 2019.
- 17 May 2019 New trial record